A presenting author offers greater study insights into this novel therapy for the treatment of serious infections.
Cefiderocol (CFDC) is a novel siderophore cephalosporin used to treat complicated urinary tract infections and it is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
The results of the phase 3 CREDIBLE-CR study, which examined the efficacy and safety of cefiderocol for the treatment of serious infections, were reported this week at ID WEEK 2020.
At the conference, cefiderocol was covered in 2 posters, “Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study,”and “Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies.” It was also presented in an oral abstract, titled, “Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study.”
One of the study’s coauthors, Thomas Lodise, PharmD, PhD, is a professor of Pharmacy Practice at Albany College of Pharmacy and Health Sciences and an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York, spoke to Contagion® during IDWeek2020 about the parameters of the CREDIBLE-CR study and offered significant insights into its important findings.
